Notable Labs Notable Labs
  • ABOUT
    • ABOUT US
    • OUR MISSION
    • LEADERSHIP
    • BOARD OF DIRECTORS
  • PLATFORM & PIPELINE
    • PREDICTIVE PRECISION MEDICINE PLATFORM
    • VOLASERTIB & FOSCICLOPIROX
  • NEWS
    • All News
    • Investor Events and Presentations
    • Press Releases
    • Scientific Presentations & Publications
    • Content Search
  • Investors
    • Investor Overview
    • SEC Filings
    • Financials
    • Governance
    • IR Contacts
    • Partnership
    • Stock Information
  • Careers
  1. You are here:  
  2. Scientific Posters
  3. Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients
Details
Category: Scientific Presentations
01.Jul

Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients

SY-1425 (tamibarotene) is an oral, potent and selective synthetic RARα agonist previously approved for the treatment of relapsed/refractory acute promyelocytic leukemia (APL) in Japan. Given preclinical evidence of SY-1425 sensitive AML cell lines and patient samples with RARA pathway activation defined by elevated RARA or IRF8, SY-1425 is being...

Viewable PDF:

CLICK HERE

 

To learn more, share ideas, or join our mission.
Contact us today!

CONNECT WITH US

  • PRIVACY POLICY
  • TERM OF USE
  • COOKIE STATEMENT
  • INVESTOR OVERVIEW
  • CAREERS
  • CONTACT US

Copyright © 2023 Notable

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.

Accept Decline
Cookie Statement